Emergent BioSolutions executive vice president Adam Havey said Emergent is pleased that PreviThrax has met all the key milestones necessary for BARDA to exercise the contract option.
"We look forward to continuing to work with BARDA to develop the medical countermeasures it believes are necessary to address the nation’s security requirements," Havey added.
Since the contract inception in 2010, Emergent has developed PreviThrax, which includes manufacturing yield increase, transferring of the manufacturing process to single-use bioreactors mode and Baltimore manufacturing facility.
The company has also developed the vaccine candidate for both liquid and dry formulations and meeting stability at elevated temperatures.
The vaccine candidate is based on the work of the US Army Medical Research Institute of Infectious Diseases and has also received funding from the National Institute of Allergy and Infectious Diseases.